Anne Fabienne Weitsch
Keine laufenden Positionen mehr
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Michel Vandevelde | M | - |
H-Phar NV
 H-Phar NV Pharmaceuticals: MajorHealth Technology H-PHAR SA was founded in 2002 to develop products based on Hubriphar SA 'Know How', in particular, a drug (Azodicarbonamide) inactivating the retroviral nucleocapside Protein 7 (NCp7) opening a new therapeutic route to treat mutated HIV resistant to the actual therapy combining at least three active medicinal products. H-Phar is a pharmaceutical research company that develops candidate drugs based on its own worldwide patented technology. Through, knowledge, creativity and integrity, H-Phar aims to preserve and improve human health by offering treatments to everyone everywhere. H-Phar is active in four operating areas include preclinical research focusing on the development of anti-viral applications of the so-called 'zinc finger ejector' in the domain of hemorrhagic fever (arenaviruses) and oncoviruses (HPV**), preclinical research focusing on the development of immune-modulator drugs inhibiting graft rejection, clinical development of an anti-HIV*drug based on a totally new mechanism of action, Vaccine evaluation of a dendritic cell loaded with HPH116 killed virus vaccine for immunological responses boost. H-Phar studies are compliant with OCDE Guidelines and ICH/GMP/GLP/GCP rules. H-Phar has build partnerships with opinion leaders in major institutions in Belgium, Europe and the US. | 9 Jahre |
| Hélène Margery | F | - |
H-Phar NV
H-Phar NV Pharmaceuticals: MajorHealth Technology H-PHAR SA was founded in 2002 to develop products based on Hubriphar SA 'Know How', in particular, a drug (Azodicarbonamide) inactivating the retroviral nucleocapside Protein 7 (NCp7) opening a new therapeutic route to treat mutated HIV resistant to the actual therapy combining at least three active medicinal products. H-Phar is a pharmaceutical research company that develops candidate drugs based on its own worldwide patented technology. Through, knowledge, creativity and integrity, H-Phar aims to preserve and improve human health by offering treatments to everyone everywhere. H-Phar is active in four operating areas include preclinical research focusing on the development of anti-viral applications of the so-called 'zinc finger ejector' in the domain of hemorrhagic fever (arenaviruses) and oncoviruses (HPV**), preclinical research focusing on the development of immune-modulator drugs inhibiting graft rejection, clinical development of an anti-HIV*drug based on a totally new mechanism of action, Vaccine evaluation of a dendritic cell loaded with HPH116 killed virus vaccine for immunological responses boost. H-Phar studies are compliant with OCDE Guidelines and ICH/GMP/GLP/GCP rules. H-Phar has build partnerships with opinion leaders in major institutions in Belgium, Europe and the US. | 9 Jahre |
| Chong Kiat Lim | M | 68 |
University of Cambridge
| 7 Jahre |
| Gregory Winter | M | 73 |
University of Cambridge
| 7 Jahre |
| Robert J. West | M | - |
University of Cambridge
| 6 Jahre |
| Gareth Beynon | M | - |
University of Cambridge
| 6 Jahre |
| Adam C. Baker | M | - |
University of Cambridge
| 5 Jahre |
| Belita S. Ong | F | - |
University of Cambridge
| 4 Jahre |
| Luc Jean Edouard Argand | M | 76 |
University of Geneva
| 4 Jahre |
| Jean-Luc Herbez | M | - |
University of Geneva
| 8 Jahre |
| Angus Porter | M | 67 |
University of Cambridge
| 4 Jahre |
| Michael John Wilson | M | - |
University of Cambridge
| 8 Jahre |
| Steve Young | M | - |
University of Cambridge
| 7 Jahre |
| Mike Gunn | M | - |
University of Cambridge
| 9 Jahre |
| Joanna Mary Gordon Perry | F | 67 |
University of Cambridge
| 3 Jahre |
| James Edward Smith | M | 71 |
University of Cambridge
| 3 Jahre |
| Steve M. Hobbs | M | - |
University of Cambridge
| 4 Jahre |
| John Katsaounis | M | - |
University of Geneva
| 4 Jahre |
| Francis McCormick | M | 73 |
University of Cambridge
| 3 Jahre |
| Dominique Rochat | M | 75 |
University of Geneva
| 3 Jahre |
| Andrew Unitt | M | 66 |
University of Cambridge
| 4 Jahre |
| Philip Atkin | M | - |
University of Cambridge
| 4 Jahre |
| David Waimann | M | - |
University of Cambridge
| 3 Jahre |
| Brij Mohan Tirath R. Kataria | M | - |
University of Cambridge
| 1 Jahre |
| Peter Highfield | M | - |
University of Cambridge
| 4 Jahre |
| Anthony Mark Savill | M | - |
University of Cambridge
| 3 Jahre |
| David Harrison | M | - |
University of Cambridge
| 1 Jahre |
| Nigel Smethers | M | - |
University of Cambridge
| 4 Jahre |
| Richard Burnett-Hall | M | - |
University of Cambridge
| 1 Jahre |
| Jörg Buchmüller | M | 76 |
University of Geneva
| 1 Jahre |
| Paul Young | M | 68 |
University of Cambridge
| 4 Jahre |
| Paul Hanworth | M | - |
University of Cambridge
| 3 Jahre |
| Tony H. J. Quick | M | 68 |
University of Cambridge
| 3 Jahre |
| Martin Smith | M | - |
University of Cambridge
| 7 Jahre |
| John Buchanan | M | 72 |
University of Cambridge
| 4 Jahre |
| Krishna N Ganesh | M | - |
University of Cambridge
| 3 Jahre |
| Nigel Keith Anthony Standish Vaz | M | 67 |
University of Cambridge
| 4 Jahre |
| Mark Wainwright Todd | M | 69 |
University of Cambridge
| 4 Jahre |
| Robert Gresham Gray | M | 70 |
University of Cambridge
| 4 Jahre |
| John Ryding | M | - |
University of Cambridge
| 4 Jahre |
| Dominique Amaudruz Guiramand | F | 70 |
University of Geneva
| 3 Jahre |
| Steven C. Schroer | M | - |
University of Cambridge
| 3 Jahre |
| Tong Boon Quek | M | 68 |
University of Cambridge
| 4 Jahre |
| Jean-Claude E. Gehret | M | 76 |
University of Geneva
| 3 Jahre |
| Ilan Hayim | M | 73 |
University of Geneva
| 4 Jahre |
| Hwee Hua Lim | F | 65 |
University of Cambridge
| 4 Jahre |
| Alan Colman | M | 75 |
University of Cambridge
| 3 Jahre |
| Alexandre Davidoff | M | - |
University of Geneva
| 3 Jahre |
| Mohamed Ibrahim Mahmoud Mohamed | M | 90 |
University of Geneva
| 3 Jahre |
| Philip Hanson | M | 67 |
University of Cambridge
| 4 Jahre |
| William Graham Cooper | M | 67 |
University of Cambridge
| 1 Jahre |
| Daniel Lew | M | 76 |
University of Geneva
| 3 Jahre |
| Jean-Pierre Pieren | M | 81 |
University of Geneva
| 4 Jahre |
| Patrick Mahy | M | - |
H-Phar NV
H-Phar NV Pharmaceuticals: MajorHealth Technology H-PHAR SA was founded in 2002 to develop products based on Hubriphar SA 'Know How', in particular, a drug (Azodicarbonamide) inactivating the retroviral nucleocapside Protein 7 (NCp7) opening a new therapeutic route to treat mutated HIV resistant to the actual therapy combining at least three active medicinal products. H-Phar is a pharmaceutical research company that develops candidate drugs based on its own worldwide patented technology. Through, knowledge, creativity and integrity, H-Phar aims to preserve and improve human health by offering treatments to everyone everywhere. H-Phar is active in four operating areas include preclinical research focusing on the development of anti-viral applications of the so-called 'zinc finger ejector' in the domain of hemorrhagic fever (arenaviruses) and oncoviruses (HPV**), preclinical research focusing on the development of immune-modulator drugs inhibiting graft rejection, clinical development of an anti-HIV*drug based on a totally new mechanism of action, Vaccine evaluation of a dendritic cell loaded with HPH116 killed virus vaccine for immunological responses boost. H-Phar studies are compliant with OCDE Guidelines and ICH/GMP/GLP/GCP rules. H-Phar has build partnerships with opinion leaders in major institutions in Belgium, Europe and the US. | - |
| Geoffrey Hale | M | - |
University of Cambridge
| 3 Jahre |
| Hugh Nineham | M | - |
University of Cambridge
| 3 Jahre |
| Chris Hills | M | - |
University of Cambridge
| 4 Jahre |
| Gordon Cudmore | M | - |
University of Cambridge
| 3 Jahre |
| Desmond Radlein | M | 74 |
University of Cambridge
| 3 Jahre |
| Ian Metcalfe | M | 66 |
University of Cambridge
| 3 Jahre |
| Graham Keniston-Cooper | M | - |
University of Cambridge
| 4 Jahre |
| Mark Christopher Greaves | M | 67 |
University of Cambridge
| 4 Jahre |
| Guilherme Brafman | M | - |
University of Cambridge
| 3 Jahre |
| Jonathan Jones | M | - |
University of Cambridge
| 3 Jahre |
| Reyaz A. Ahmad | M | - |
University of Cambridge
| 5 Jahre |
| Pierre Francotte | M | 67 |
University of Cambridge
| 4 Jahre |
| Gerard Evan | M | - |
University of Cambridge
| 4 Jahre |
| Frank Christian Wignall | M | 68 |
University of Cambridge
| 4 Jahre |
| Timothy Norman Wallach | M | - |
University of Cambridge
| 4 Jahre |
| Paul Averback | M | 73 |
University of Cambridge
| 3 Jahre |
| David Turnbull | M | 69 |
University of Cambridge
| 4 Jahre |
| Massimo Giovanni Prelz Oltramonti | M | 70 |
University of Geneva
| 4 Jahre |
| Dominic Casserley | M | 67 |
University of Cambridge
| 4 Jahre |
| David Dew | M | 69 |
University of Cambridge
| 4 Jahre |
| Charles Baker | M | 66 |
University of Cambridge
| 4 Jahre |
| David Godden | M | - |
University of Cambridge
| 4 Jahre |
| Peter Bazalgette | M | 71 |
University of Cambridge
| 4 Jahre |
| Claude Messulam | M | 73 |
University of Geneva
| 1 Jahre |
| Andrew Tomlinson | M | - |
University of Cambridge
| 4 Jahre |
| Suet-Fern Lee | F | 66 |
University of Cambridge
| 3 Jahre |
| Bella Ann Almeida | F | 68 |
University of Cambridge
| 3 Jahre |
| David Sidwell | M | 71 |
University of Cambridge
| 4 Jahre |
| Didier Georges | M | - |
H-Phar NV
H-Phar NV Pharmaceuticals: MajorHealth Technology H-PHAR SA was founded in 2002 to develop products based on Hubriphar SA 'Know How', in particular, a drug (Azodicarbonamide) inactivating the retroviral nucleocapside Protein 7 (NCp7) opening a new therapeutic route to treat mutated HIV resistant to the actual therapy combining at least three active medicinal products. H-Phar is a pharmaceutical research company that develops candidate drugs based on its own worldwide patented technology. Through, knowledge, creativity and integrity, H-Phar aims to preserve and improve human health by offering treatments to everyone everywhere. H-Phar is active in four operating areas include preclinical research focusing on the development of anti-viral applications of the so-called 'zinc finger ejector' in the domain of hemorrhagic fever (arenaviruses) and oncoviruses (HPV**), preclinical research focusing on the development of immune-modulator drugs inhibiting graft rejection, clinical development of an anti-HIV*drug based on a totally new mechanism of action, Vaccine evaluation of a dendritic cell loaded with HPH116 killed virus vaccine for immunological responses boost. H-Phar studies are compliant with OCDE Guidelines and ICH/GMP/GLP/GCP rules. H-Phar has build partnerships with opinion leaders in major institutions in Belgium, Europe and the US. | - |
| William Gilfillan Lamarque | M | 70 |
University of Cambridge
| 4 Jahre |
| Alastair K. Livesey | M | 67 |
University of Cambridge
| 4 Jahre |
| Clive Partridge | M | - |
University of Cambridge
| 4 Jahre |
| William Spurgin | M | - |
University of Cambridge
| 4 Jahre |
| Tony Alves | M | 62 |
University of Cambridge
| 4 Jahre |
| John David Porter | M | - |
University of Cambridge
| 4 Jahre |
| Jonathan E. Clegg | M | - |
University of Cambridge
| 4 Jahre |
| Beat W. Hess | M | 74 |
University of Geneva
| 3 Jahre |
| Lim Andy | M | 66 |
University of Cambridge
| 4 Jahre |
| John Bailey | M | - |
University of Cambridge
| 3 Jahre |
| Jonathan Charles Kingsman | M | 67 |
University of Cambridge
| 2 Jahre |
| Charles E. Forrest | M | - |
University of Cambridge
| 3 Jahre |
| Manu Bhaskaran | M | 66 |
University of Cambridge
| 4 Jahre |
| Peter Jackson | M | 62 |
University of Cambridge
| 4 Jahre |
| Fiona Claire Reynolds | F | 66 |
University of Cambridge
| 4 Jahre |
| Andrew Galazka | M | 69 |
University of Cambridge
| 3 Jahre |
| Richard Greer | M | - |
University of Cambridge
| 3 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigtes Königreich | 81 | 81,00% |
| Schweiz | 15 | 15,00% |
| Belgien | 4 | 4,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Anne Fabienne Weitsch
- Persönliches Netzwerk
